Q2 FY2026 EarningsQ2 FY2026 results missed consensus on the bottom line, with a wider-than-expected operating cash outflow of $20.8M (AUD ~$31M) vs. the -$16.4M consensus. While R&D scaled to $23.4M to support the pivotal PARADIGM Trial, the initiation of U.S. recruitment and CMS reimbursement eligibility mark critical de-risking milestones. Revenue remained immaterial as the company remains in the pre-commercial clinical phase, focusing capital on the DurAVR® THV regulatory pathway.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Anteris Tech Global(AVR) the Revenue is 984.6 K (+58.95%), Miss estimate;the EBIT is -30.25 M (-44.5%), Miss estimate;the EPS is -0.3 (+48.28%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.00B58.95%
0.00B133.97%
-0.00B75.02%
EBITMiss expectations
-0.03B44.50%
-0.02B7.33%
-0.01B51.83%
EPSMiss expectations
-0.348.28%
-0.206764.37%
-0.093316.09%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf